SCHEMBL20209632

SCHEMBL20209632

FC(F)(F)c1ccc(-c2cn3c(C(F)(F)F)ncc3cn2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 3/20 0.49
CYP1A2 P05177 3/20 0.43
MKNK1 Q9BUB5 1/20 0.41
MKNK2 Q9HBH9 1/20 0.41
KDM1A O60341 1/20 0.40
MAOB P27338 1/20 0.40
ADORA2A P29274 1/20 0.39
KIF11 P52732 3/20 0.38
CA12 O43570 1/20 0.36
CA9 Q16790 1/20 0.36
IDO1 P14902 1/20 0.36
TDO2 P48775 1/20 0.36
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 1/20 0.35
POLB P06746 1/20 0.35
HPGD P15428 1/20 0.35
NFKB1 P19838 1/20 0.35
RAB9A P51151 1/20 0.35
GFER P55789 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12945003 0.83 SCN5A (0.69) SCN5ACYP1A2KIF11KDM4EALDH1A1
SCHEMBL20209019 0.82 SCN5A (0.73) SCN5ACYP1A2ADORA2ACA12CA9
SCHEMBL26460777 0.80 SCN5A (0.59) SCN5ACYP1A2ADORA2AKDM4ENPC1
SCHEMBL26460787 0.80 SCN5A (0.59) SCN5ACYP1A2ADORA2AKDM4ENPC1
SCHEMBL20203995 0.79 CYP1A2 (0.67) SCN5ACYP1A2MKNK1MKNK2KDM1A
SCHEMBL20209010 0.76 CYP1A2 (0.54) SCN5ACYP1A2ALDH1A1
SCHEMBL20209633 0.76 ADORA2A (0.41) SCN5ACYP1A2MKNK1MKNK2KDM1A
SCHEMBL20208584 0.74 MKNK1 (0.51) SCN5ACYP1A2MKNK1MKNK2KDM1A
SCHEMBL23524384 0.73 MKNK1 (0.50) SCN5ACYP1A2MKNK1MKNK2KDM1A
SCHEMBL20208572 0.73 MKNK1 (0.53) SCN5ACYP1A2MKNK1MKNK2KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230134428-A1 FUSED HETEROARYL COMPOUNDS, AND METHODS THEREOF FOR TREATING DISEASES, DISORDERS, AND CONDITIONS RELATING TO ABERRANT FUNCTION OF A SODIUM CHANNEL PRAXIS PRECISION MEDICINES, INC. 2023-05-04 US disclosed
WO-2018098491-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230134428-A1 FUSED HETEROARYL COMPOUNDS, AND METHODS THEREOF FOR TREATING DISEASES, DISORDERS, AND CONDITIONS RELATING TO ABERRANT FUNCTION OF A SODIUM CHANNEL SCN1A, SCN3A, SCN2A SCN5A 7/4885CYP1A2 3251/4885MKNK1 2964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.